• 1.

    Wanner C, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:32334.

  • 2.

    Heerspink HJ, et al.. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28:36875.

  • 3.

    Heerspink HJ, et al.. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 2016; 18:5907.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Fernández-Balsells MM, Sojo-Vega L, Ricart-Engel W. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377:2098.

  • 5.

    Kodera R, Shikata K. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor. J Diabetes Investig 2016; 7:2931.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Mosenzon O, et al.. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 2017; 40:6976.

  • 7.

    Cornel JH, et al.. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care 2016; 39:230410.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther Adv Endocrinol Metab 2013; 4:95105.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Kodera R, et al.. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54:96578.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377:839848.

    • PubMed
    • Search Google Scholar
    • Export Citation

Newer diabetic medications and the kidney

Sonali Gupta Sonali Gupta, MD, is a resident, and

Search for other papers by Sonali Gupta in
Current site
Google Scholar
PubMed
Close
and
Joseph Mattana Joseph Mattana, MD, is Chairman, Department of Medicine, at St. Vincent’s Medical Center in Bridgeport, CT. Dr. Mattana is a member of the KN Editorial Advisory Board.

Search for other papers by Joseph Mattana in
Current site
Google Scholar
PubMed
Close
Restricted access
Save